Prognostic Indicators of Survival in Sinonasal Diffuse Large B‐Cell Lymphoma: A National Cancer Database Analysis

Objectives/Hypothesis This study offers an update on the epidemiologic and prognostic factors and treatment‐specific outcomes in patients diagnosed with sinonasal diffuse large B‐cell lymphoma (DLBCL). Study Design Retrospective cohort study. Methods National Cancer Database was queried from 2004 to 2016 for patients with sinonasal DLBCL. Univariate Kaplan‐Meier and multivariate Cox‐regression analyses were performed to evaluate the association of suspected prognostic factors with overall survival (OS). Results A total of 2,222 patients with sinonasal DLBCL were analyzed. OS was 62% at 5 years and 42% at 10 years. Prognostic factors associated with increased survival included African‐American race (HR: 0.48, 95% CI: 0.33–0.70), chemotherapy (HR: 0.30, CI: 0.25–0.35), and radiation (HR: 0.80, CI: 0.69–0.93). Prognostic factors associated with decreased survival included patients with Charlson‐Deyo scores of 1 (HR: 1.51, CI: 1.25–1.84), 2 (HR: 2.25, CI: 1.67–3.03), and 3 (HR: 2.36, CI: 1.49–3.74) and patients with Lugano stage III (HR: 1.69, CI: 1.09–2.62) and IV (HR: 1.96, CI: 1.46–2.64) disease. Stage‐based split multivariate analysis was performed and revealed chemotherapy was independently associated with increased OS in patients with stage I (HR: 0.24, CI: 0.19–0.30), II (HR: 0.17, CI: 0.11–0.28), and IV (HR: 0.41, CI: 0.26–0.64) disease. Radiotherapy was independently associated with increased OS in patients with stage I disease only (HR: 0.67, CI: 0.55–0.83), while immunotherapy was an independent prognostic factor in patients with stage IV disease only (HR: 0.60, CI: 0.37–0.98). Conclusion This study is the largest to date to analyze the association of demographic features and treatment modalities with OS in patients with sinonasal DLBCL. It is the first to investigate the association of immunotherapy with OS in this population. A combination treatment of immunochemotherapy or radioimmunochemotherapy confers increased survival, particularly in patients with advanced disease. Level of Evidence 4 Laryngoscope, 132:1515–1522, 2022